新血府逐瘀软胶囊对不稳定型心绞痛血瘀征象及ox-LDL、hs-CRP影响的临床研究  

Clinical Research of New Xuefuzhuyu Capsule on Blood Stasis Syndrome of Unstable Angina Pectoris,Ox-LDL and HS-CRP

作　　者：林红丽[1] 吉中强[1] 纪文岩[1] 

机构地区：[1]青岛海慈医疗集团,山东青岛266033

出　　处：《世界中西医结合杂志》2010年第3期230-232,共3页World Journal of Integrated Traditional and Western Medicine

摘　　要：目的探讨新血府逐瘀软胶囊对不稳定型心绞痛(UA)血瘀征象及氧化型低密度脂蛋白(ox-LDL)、高敏C反应蛋白(hs-CRP)的影响。方法60例(UA)患者随机分为治疗组(n=30)和对照组(n=30),另设健康组(n=30)。对照组予以常规治疗(硝酸酯类、钙离子拮抗剂、β-受体阻制剂、血管紧张素转换酶抑制剂及肠溶阿司匹林),治疗组在对照组常规治疗的基础上加服新血府逐瘀软胶囊,两组均用药1个月。分别在治疗前后观察其血瘀征象并检测ox-LDL、hs-CRP水平。结果治疗组与对照组治疗后心绞痛、血瘀征象总有效率比较,差异均有统计学意义;治疗组治疗后血清ox-LDL、hs-CRP的水平均明显低于对照组(P<0.05)。结论新血府逐瘀软胶囊可以通过改善UA患者血瘀征象及降低ox-LDL、hs-CRP水平的途径,稳定斑块、抑制脂质过氧化、抗血管内皮炎症、改善内皮功能从而提高对UA的疗效。Objective To explore the impacts of new xuefuzhuyu capsule on blood stasis syndrome of unstable angina pectoris as well as ox-LDL and hs-CRP.Methods 60 cases of unstable angina pectoris were randomized into treatment group（n=30）and control group（n=30）.Additionally,a health group（n=30）was set up.The control group was treated conventionally（such as nitrates,calcium antagonists,β-receptor blocker agents,angiotensin-converting enzyme inhibitors and aspirin）.The treatment group was treated with new xuefuzhuyu capsule supplemented on the basis of conventional therapy as control group.The two groups were all medicated for 1 month.Blood stasis syndromes,ox-LDL and hs-CRP levels were observed before and after treatment separately.Results The significant statistical difference presented in the total effective rates of angina pectoris and blood stasis syndromes in comparison between treatment group and control group.The serum ox-LDL and hs-CRP levels in treatment were significantly lower than those in control group after treatment（P0.05）.Conclusion The new xuefuzhuyu capsule stabilizes plaques,inhibits lipid peroxidation and resists vascular endothelial inflammation so that the efficacy of unstable angina pectoris can be improved via relieving blood stasis syndromes and decreasing ox-LDL and hs-CRP levels.

关 键 词：不稳定型心绞痛 血瘀 OX-LDL HS-CRP 

分 类 号：R927.2[医药卫生—药学]